|Mr. Steven Medlicott||CFO, Fin. Director & Exec. Director||333k||N/A||1965|
|Dr. Raymond Barlow B.Sc. (Hons), Ph.D., MBA||CEO & Director||N/A||N/A||1969|
|Mrs. Susan M. Steven||Company Sec.||N/A||N/A||1963|
e-Therapeutics plc engages in the discovery and development of drugs through its proprietary platform in network pharmacology and chemical biology. It focuses on the discovery of drugs for cancer. The company's drug candidates include ETS2101, which is in Phase Ib clinical trial for the treatment of hepatocellular and pancreatic cancer. It also develops ETS6103; and ETX1153c products. The company was founded in 2001 and is based in Long Hanborough, the United Kingdom.
e-Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.